The
global Biomarkers Market size
is expected to reach over USD 129.4 billion by 2027, according to a new study
conducted by Grand View Research Inc. It is anticipated to exhibiting a CAGR of
13.7%, during the forecast period. Factors, such as increasing collaborations
and funds for R&D activities, rising consumer awareness, a widening patient
base, and technological advancements collectively augmenting market growth.
The
drug discovery segment contributed the highest revenue in 2019. Pharmaceutical
companies focus on extensive R&D initiatives for the development of
targeted therapeutics. Coordinated strategic efforts on biomarker development
remain a searing trend among drug manufacturers, academic research
institutions, commercial R&D organizations, nonprofitable health
foundations, and federal government biomedical regulatory and research
agencies.
North
America continued to lead the biomarkers market in 2019, driven by an
amplifying demand for personalized medicines, high disease prevalence, and
proactive government initiatives. It is expected to maintain its lead over the
forecast period. Asia Pacific is positioned to witness the fastest CAGR, over
the forecast period, spearheaded by India.
Some
key market players include Abbott; F. Hoffmann-La Roche Ltd.; Qiagen; Siemens
Healthcare Private Limited; Thermo Fisher Scientific, Inc.; Bio-Rad
Laboratories, Inc.; Johnson & Johnson Services, Inc; Agilent Technologies,
Inc.; and Epigenomics AG. The players are developing novel kits and therapies
and drugs to target population in the areas with high unmet clinical needs.
Browse
Details of Report @ https://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Further key findings from the study suggest:
- Safety
biomarkers captured more than 41% market share in 2019, driven by
increasing awareness regarding routine healthcare checkups and reduction
in drug attrition
- Validation
biomarkers is expected to demonstrate the fastest CAGR through to 2027
- Personalized
medicine is likely to expand at a CAGR of 14.8% over the forecast period
due to consumer awareness and preferences
- Cancer
dominated the disease segment in 2019, driven by a high disease burden and
presence of a strong pipeline
- Cardiovascular
disease segment is projected to witness the fastest growth in the
forthcoming years, supported by the growing obese population base and
sedentary lifestyles
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment